New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:00 EDTXOMAXOMA Phase III gevokizumab trial likely to miss endpoint, says Summer Street
Summer Street believes Xoma's Phase III trial for gevokizumab will likely not meet the primary endpoint of being effective in treating eye involvement in patients with BehÁetís disease. The firm says prior clinical trials indicate that the product is only a weak anti-inflammatory agent.
News For XOMA From The Last 14 Days
Check below for free stories on XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
12:12 EDTXOMAXOMA management to meet with Piper Jaffray
Meetings to be held in Chicago on September 17 and in Minneapolis on September 18 hosted by Piper Jaffray.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use